Giant cell tumour of the bone in children and adolescents: Report of 11 cases
DOI:
https://doi.org/10.1016/j.rccot.2017.06.006Keywords:
giant cell tumour of the bone, child, adolescent, denosumabAbstract
Background: Giant cell tumours (GCT) of the bone are benign and consist of aggressive local growth with rare metastatic disease. Its reported incidence in the immature skeleton is less than 10%, ranging from 1.8% to 10.6%. Few GCT series have been reported in the immature skeleton. In our ¿country?, the overall incidence and impact of GCT in these patients is unknown. A series of 11 cases is presented, demonstrating their demographic characteristics, treatment, and follow-up.
Methods: Between the year 2000 and 2014, out of a total of77 patients with GCT, 11 of them presented with skeletal immaturity at the time of diagnosis. These patients were treated and followed-up in our institution. A retrospective analysis was performed. All patients had histologically confirmed GCT, and in all cases a review was made of the X-rays, chest CT and, bone scans, and MRI scans of the compromised region. Skeletal maturity was determined if there was open physes at the time of diagnosis. The mean follow-up was 6.6 years (range 2 to 10 years)
Results: A total of 8 females and 3 males, with a mean age of 14.8 years at the time of diagnosis, presented with a GCT. The incidence of GCT in the skeletally immature patient was 7%. The compromised site was: around the knee in 8 cases, of which 4 were in the distal femur and 4 in the proximal tibia, with two in the proximal humerus and one in a metatarsal. All patients were treated with allografts. Nine received structural allografts and two osteochondral allografts. One patient received denosumab. Seven out of the 11 patients had no complications. Three did have complications. One had a local recurrence, one required removal of hardware material, and a third presented with a fracture. The patient treated with osteochondral allograft presented with a traumatic fracture, which consolidated without surgical management.
Discussion: GCT in the skeletally immature patient is rare, and poses a challenge for the surgeon. The impact on our practice is similar to that reported in the literature. In our series, successful reconstruction was achieved in the majority of patients, with one local recurrence. Allograft reconstruction is a good method of treatment, with successful results. The modality of our study limits our ability to assess effectiveness, and the low incidence in this age group limits the number of cases presented. A prospective study could further consider other aspects, such as length discrepancy and local recurrence, and functional scales could improve our knowledge about the impact of treatment in this population.
Evidence level: IV.
Downloads
References
Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. J Am Acad Orthop Surg. 2013;21:118-26. https://doi.org/10.5435/JAAOS-21-02-118
Coley BL. Giant cell tumor (osteoclastoma). En: Coley BL, editor. Neoplasms of bone and related conditions. 2 nd Ed. New York, NY: Hoeber; 1960. p. 196-235.
Jaffe HL. Giant-cell tumour (osteoclastoma) of bone: Its pathologic delimitation and the inherent clinical implications. Ann R Coll Surg Engl. 1953;13:343-55.
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987;69:106-14. https://doi.org/10.2106/00004623-198769010-00018
Lichtenstein L. Bone tumors. 2nd Ed. St. Louis: Mosby; 1959.
Domovitov SV, Healey JH. Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol. 2010;17: 694-701. https://doi.org/10.1245/s10434-009-0803-z
Puri A. Giant cell tumor of bone in children and adolescents. J Pediatr Orthop. 2007;27:635-9. https://doi.org/10.1097/BPO.0b013e3181425629
Picci P, Manfrini M, Zucchi V, Gherlinzoni F, Rock M, Bertoni F, et al. Giant-cell tumor of bone in skeletally immature patients. J Bone Joint Surg Am. 1983;65:486-90. https://doi.org/10.2106/00004623-198365040-00009
Sánchez-Torres LJ. Tumor: óseo de células gigantes en pacientes de menos de 20 años de edad. Revista Mexicana de Ortopedia Pediátrica. 2012;14:26-30.
Miller G, Bettelli G, Fabbri N, Capanna R. Curettage of giant cell tumor of bone. Introduction-material and methods. Chir Organi Mov. 1990;75 suppl 1:203.
Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am. 1999;81:811-20. https://doi.org/10.2106/00004623-199906000-00008
Prosser H, Baloch KG, Tillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone. Clin Orthop Relat Res. 2005;435:211-8. https://doi.org/10.1097/01.blo.0000160024.06739.ff
Sherman M, Fabricius R. Giant-cell tumor in the metaphysis in a child. Report of an unusual case. J Bone Joint Surg Am. 1961;4:1225-9, 43-A. https://doi.org/10.2106/00004623-196143080-00013
Peison B. Metaphyseal giant-cell tumor in a girl of 14. Radiology. 1976;118:145-6. https://doi.org/10.1148/118.1.145
Ontell FK, Ivanovic M, Ablin DS, Barlow TW. Bone age in children of diverse ethnicity. AJR Am J Roentgenol. 1996;167:1395-8. https://doi.org/10.2214/ajr.167.6.8956565
Schmeling A, Schulz R, Danner B, Rösing FW. The impact of economic progress and modernization in medicine on the ossification of hand and wrist. Int J Legal Med. 2006;120:121-6. https://doi.org/10.1007/s00414-005-0007-4
Balke M, Hardes J. Denosumab: a breakthrough in treatment of giant-cell tumour of bone. Lancet Oncol. 2010;11:218-9. https://doi.org/10.1016/S1470-2045(10)70027-9
Xu SF. Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol. 2013;20:442-7. https://doi.org/10.3747/co.20.1497
Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11:275-80. https://doi.org/10.1016/S1470-2045(10)70010-3
Blay J, Chawla SP, Martin Broto J, Choy E, Dominikus M, Engellau J, et al. Denosumab safety and efficacy in giant cell tumor of bone (gctb): interim results from a phase II study [abstract 10034]. J Clin Oncol. 2011;29. Disponible en: http://www.asco.org/ASCOv2/Meetings/Abstracts https://doi.org/10.1200/jco.2011.29.15_suppl.10034
Thomas D, Carriere P, Jacobs I. Safety of denosumab in giant cell tumour of bone. Lancet Oncol. 2010;11:815. 22. Kyrgidis A, Toulis K. Safety and efficacy of denosumab in giantcell tumour of bone. Lancet Oncol. 2010;11:513-4. https://doi.org/10.1016/S1470-2045(10)70170-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Revista Colombiana de ortopedia y traumatología

This work is licensed under a Creative Commons Attribution 3.0 Unported License.